Skip to main content
SpringerLink
Log in

Spinal muscular atrophy: Advances in research and consensus on care of patients

  • Published:
Current Treatment Options in Neurology Aims and scope Submit manuscript

Opinion statement

Spinal muscular atrophy (SMA) is an autosomal recessive disease characterized by degeneration of spinal cord motor neurons and muscular atrophy. Advances in recent research have led to understanding of the molecular genetics of SMA. Therapeutic strategies have been developed according to the unique genomic structure of the SMN genes. Three groups of compounds have been identified as therapeutic candidates. One group was identified before the molecular genetics of SMA was understood, chosen on the basis of their effectiveness in similar neurologic disorders. The second group was identified based on their ability to modify SMN2 gene expression. Several of these agents are currently in clinical trials. A third group, identified by large-scale drug screening, is still under preclinical investigation. In addition, other advances in medical technology have led to the publication of a consensus statement regarding the care of SMA patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References and Recommended Reading

  1. Munsat TL: International SMA Collaboration. Neuromuscul Disord 1991, 1:81.

    Article  Google Scholar 

  2. Russman BS: Spinal muscular atrophy: clinical classification and disease heterogeneity. J Child Neurol 2007, 22:946–951.

    Article  PubMed  Google Scholar 

  3. Lefebvre S, Burglen L, Reboullet S, et al.: Identification and characterization of a spinal muscular atrophy-determining gene. Cell 1995, 80:155–165.

    Article  PubMed  CAS  Google Scholar 

  4. Burglen L, Lefebvre S, Clermont O, et al.: Structure and organization of the human survival motor neurone (SMN) gene. Genomics 1996, 32:479–482.

    Article  PubMed  CAS  Google Scholar 

  5. Hahnen E, Forkert R, Marke C, et al.: Molecular analysis of candidate genes on chromosome 5q13 in autosomal recessive spinal muscular atrophy: evidence of homozygous deletions of the SMN gene in unaffected individuals. Hum Mol Genet 1995, 4:1927–1933.

    Article  PubMed  CAS  Google Scholar 

  6. Lorson CL, Androphy EJ: An exonic enhancer is required for inclusion of an essential exon in the SMA-determining gene SMN. Hum Mol Genet 2000, 9:259–265.

    Article  PubMed  CAS  Google Scholar 

  7. Chang HC, Hung WC, Chuang YJ, Jong YJ: Degradation of survival motor neuron (SMN) protein is mediated via the ubiquitin/proteasome pathway. Neurochem Int 2004, 45:1107–1112.

    Article  PubMed  CAS  Google Scholar 

  8. Andreassi C, Jarecki J, Zhou J, et al.: Aclarubicin treatment restores SMN levels to cells derived from type I spinal muscular atrophy patients. Hum Mol Genet 2001, 10:2841–2849.

    Article  PubMed  CAS  Google Scholar 

  9. Chang JG, Hsieh-Li HM, Jong YJ, et al.: Treatment of spinal muscular atrophy by sodium butyrate. Proc Natl Acad Sci U S A 2001, 98:9808–9813.

    Article  PubMed  CAS  Google Scholar 

  10. Brichta L, Hofmann Y, Hahnen E, et al.: Valproic acid increases the SMN2 protein level: a well-known drug as a potential therapy for spinal muscular atrophy. Hum Mol Genet 2003, 12:2481–2489.

    Article  PubMed  CAS  Google Scholar 

  11. Sumner CJ, Huynh TN, Markowitz JA, et al.: Valproic acid increases SMN levels in spinal muscular atrophy patient cells. Ann Neurol 2003, 54:647–654.

    Article  PubMed  CAS  Google Scholar 

  12. Grzeschik SM, Ganta M, Prior TW, et al.: Hydroxyurea enhances SMN2 gene expression in spinal muscular atrophy cells. Ann Neurol 2005, 58:194–202.

    Article  PubMed  CAS  Google Scholar 

  13. Andreassi C, Angelozzi C, Tiziano FD, et al.: Phenylbutyrate increases SMN expression in vitro: relevance for treatment of spinal muscular atrophy. Eur J Hum Genet 2004, 12:59–65.

    Article  PubMed  CAS  Google Scholar 

  14. Jarecki J, Chen X, Bernardino A, et al.: Diverse small-molecule modulators of SMN expression found by high-throughput compound screening: early leads towards a therapeutic for spinal muscular atrophy. Hum Mol Genet 2005, 14:2003–2018.

    Article  PubMed  CAS  Google Scholar 

  15. Mattis VB, Rai R, Wang J, et al.: Novel aminoglycosides increase SMN levels in spinal muscular atrophy fibroblasts. Hum Genet 2006, 120:589–601.

    Article  PubMed  CAS  Google Scholar 

  16. Lunn MR, Root DE, Martino AM, et al.: Indoprofen upregulates the survival motor neuron protein through a cyclooxygenase-independent mechanism. Chem Biol 2004, 11:1489–1493.

    Article  PubMed  CAS  Google Scholar 

  17. Hofmann Y, Lorson CL, Stamm S, et al.: Htra2-1 stimulates an exonic splicing enhancer and can restore full-length SMN expression to survival motor neuron 2 (SMN2). Proc Natl Acad Sci U S A 2000, 97:9618–9623.

    Article  PubMed  CAS  Google Scholar 

  18. Pazin MJ, Kadonaga JT: What’s up and down with histone deacetylation and transcription? Cell 1997, 89:325–328.

    Article  PubMed  CAS  Google Scholar 

  19. Gilbert J, Baker SD, Bowling MK, et al.: A phase I dose escalation and bioavailability study of oral sodium phenylbutyrate in patients with refractory solid tumor malignancies. Clin Cancer Res 2001, 7:2292–2300.

    PubMed  CAS  Google Scholar 

  20. Hahnen E, Eyupoglu IY, Brichta L, et al.: In vitro and ex vivo evaluation of second-generation histone deacetylase inhibitors for the treatment of spinal muscular atrophy. J Neurochem 2006, 98:193–202.

    Article  PubMed  CAS  Google Scholar 

  21. Avila AM, Burnett BG, Taye AA, et al.: Trichostatin A increases SMN expression and survival in a mouse model of spinal muscular atrophy. J Clin Invest 2007, 117:659–671.

    Article  PubMed  CAS  Google Scholar 

  22. Stutzmann J, Wahl F, Pratt J, et al.: Neuroprotective profile of riluzole in in vivo models of acute neurodegenerative disease. CNS Drug Rev 1997, 3:83–101.

    Article  CAS  Google Scholar 

  23. Haddad H, Cifuentes-Diaz C, Miroglio A, et al.: Riluzole attenuates spinal muscular atrophy disease progression in a mouse model. Muscle Nerve 2003, 28:432–437.

    Article  PubMed  CAS  Google Scholar 

  24. Lorson CL, Strasswimmer J, Yao JM, et al.: SMN oligomerization defect correlates with spinal muscular atrophy severity. Nat Genet 1998, 19:63–66.

    Article  PubMed  CAS  Google Scholar 

  25. Howard MT, Anderson CB, Fass U, et al.: Readthrough of dystrophin stop codon mutations induced by aminoglycosides. Ann Neurol 2004, 55:422–426.

    Article  PubMed  CAS  Google Scholar 

  26. Hua Y, Vickers TA, Baker BF, et al.: Enhancement of SMN2 exon 7 inclusion by antisense oligonucleotides targeting the exon. PLoS Biol 2007, 5(4):e73.

    Article  Google Scholar 

  27. Skordis LA, Dunckley MG, Yue B, et al.: Bifunctional antisense oligonucleotides provide a trans-acting splicing enhancer that stimulates SMN2 gene expression in patient fibroblasts. Proc Natl Acad Sci U S A 2003, 100:4114–4119.

    Article  PubMed  CAS  Google Scholar 

  28. Cartegni L, Krainer AR: Correction of disease-associated exon skipping by synthetic exon-specific activators. Nat Struct Biol 2003, 10:120–125.

    Article  PubMed  CAS  Google Scholar 

  29. Kaufmann P, Muntoni F: Issues in SMA clinical trial design: The International Coordinating Committee (ICC) for SMA Subcommittee on SMA Clinical Trial Design. Neuromuscul Disord 2007, 17:499–505.

    Article  PubMed  CAS  Google Scholar 

  30. Bertini E, Burghes A, Bushby K, et al.: 134th ENMC International Workshop: Outcome Measures and Treatment of Spinal Muscular Atrophy, 11–13 February 2005, Naarden, The Netherlands. Neuromuscul Disord 2005, 15:802–816.

    Article  PubMed  CAS  Google Scholar 

  31. Merlini L, Mazzone ES, Solari A, Morandi L: Reliability of hand-held dynamometry in spinal muscular atrophy. Muscle Nerve 2002, 26:64–70.

    Article  PubMed  Google Scholar 

  32. Iannaccone ST, Hynan LS: Reliability of 4 outcome measures in pediatric spinal muscular atrophy. Arch Neurol 2003, 60:1130–1136.

    Article  PubMed  Google Scholar 

  33. Krosschell KJ, Maczulski JA, Crawford TO, et al.: A modified Hammersmith functional motor scale for use in multi-center research on spinal muscular atrophy. Neuromuscul Disord 2006, 16:417–426.

    Article  PubMed  Google Scholar 

  34. Sumner CJ, Kolb SJ, Harmison GG, et al.: SMN mRNA and protein levels in peripheral blood: biomarkers for SMA clinical trials. Neurology 2006, 66:1067–1073.

    Article  PubMed  CAS  Google Scholar 

  35. Simard LR, Belanger MC, Morissette S, et al.: Preclinical validation of a multiplex real-time assay to quantify SMN mRNA in patients with SMA. Neurology 2007, 68:451–456.

    Article  PubMed  CAS  Google Scholar 

  36. Lunn MR, Stockwell BR: Chemical genetics and orphan genetic diseases. Chem Biol 2005, 12:1063–1073.

    Article  PubMed  CAS  Google Scholar 

  37. Wichterle H, Lieberam I, Porter JA, Jessell TM: Directed differentiation of embryonic stem cells into motor neurons. Cell 2002, 110:385–397.

    Article  PubMed  CAS  Google Scholar 

  38. Kerr DA, Llado J, Shamblott MJ, et al.: Human embryonic germ cell derivatives facilitate motor recovery of rats with diffuse motor neuron injury. J Neurosci 2003, 23:5131–5140.

    PubMed  CAS  Google Scholar 

  39. Harper JM, Krishnan C, Darman JS, et al.: Axonal growth of embryonic stem cell-derived motoneurons in vitro and in motoneuron-injured adult rats. Proc Natl Acad Sci U S A 2004, 101:7123–7128.

    Article  PubMed  CAS  Google Scholar 

  40. Miller RG, Moore DH, Dronsky V, et al.: A placebo-controlled trial of gabapentin in spinal muscular atrophy. J Neurol Sci 2001, 191:127–131.

    Article  PubMed  CAS  Google Scholar 

  41. Russman BS, Iannaccone ST, Samaha FJ: A phase 1 trial of riluzole in spinal muscular atrophy. Arch Neurol 2003, 60:1601–1603.

    Article  PubMed  Google Scholar 

  42. Kinali M, Mercuri M, Main M, et al.: Pilot trial of albuterol in spinal muscular atrophy. Neurology 2002, 59:609–610.

    PubMed  CAS  Google Scholar 

  43. Tzeng AC, Cheng J, Fryczynski H, et al.: A study of thyrotropin-releasing hormone for the treatment of spinal muscular atrophy: a preliminary report. Am J Phys Med Rehabil 2000, 79:435–440.

    Article  PubMed  CAS  Google Scholar 

  44. European Spinal Muscular Atrophy Randomized Clinical Trial II (EUROSMART II). www.enmc.org/workshop/?id=73. Accessed August 6, 2008.

  45. Brahe C, Vitali T, Tiziano FD, et al.: Phenylbutyrate increases SMN gene expression in spinal muscular atrophy patients. Eur J Hum Genet 2005, 13:256–259.

    Article  PubMed  CAS  Google Scholar 

  46. Mercuri E, Bertini E, Messina S, et al.: Pilot trial of phenyl-butyrate in spinal muscular atrophy. Neuromuscul Disord 2004, 14:130–135.

    Article  PubMed  Google Scholar 

  47. Mercuri E, Bertini E, Messina S, et al.: Randomized, double-blind, placebo-controlled trial of phenylbutyrate in spinal muscular atrophy. Neurology 2007, 68:51–55.

    Article  PubMed  CAS  Google Scholar 

  48. Brichta L, Holker I, Haug K, et al.: In vivo activation of SMN in spinal muscular atrophy carriers and patients treated with valproate. Ann Neurol 2006, 59:970–975.

    Article  PubMed  CAS  Google Scholar 

  49. Weihl CC, Connolly AM, Pestronk A: Valproate may improve strength and function in patients with type III/IV spinal muscle atrophy. Neurology 2006, 67:500–501.

    Article  PubMed  CAS  Google Scholar 

  50. Liang WC, You CY, Chang JG, et al.: The effect of hydroxyurea in spinal muscular atrophy cells and patients. J Neurol Sci 2008, 268:87–94.

    Article  PubMed  CAS  Google Scholar 

  51. Wang CH, Finkel RS, Bertini ES, et al.: Consensus statement for standard of care in spinal muscular atrophy. J Child Neurol 2007, 22:1027–1049. Available at http://jcn.sagepub.com/cgi/content/abstract/22/8/1027.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Neurology and Neurological Sciences, Stanford University Medical Center, 300 Pasteur Drive, Room A343, Stanford, CA, 94305-5235, USA

    Ching H. Wang

Authors
  1. Ching H. Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Mitchell R. Lunn
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ching H. Wang.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wang, C.H., Lunn, M.R. Spinal muscular atrophy: Advances in research and consensus on care of patients. Curr Treat Options Neurol 10, 420–428 (2008). https://doi.org/10.1007/s11940-008-0044-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11940-008-0044-7

Keywords

Search

Navigation